Non-Response to Ketamine in TRD: Clinical Correlates and Implications

Non-Response to Ketamine in TRD: Key Findings

A September 2026 peer-reviewed article (OpenAlex W7212187959) reports that a subset of patients with treatment-resistant depression (TRD) do not experience increased life engagement following ketamine treatment. The study, conducted at a tertiary psychiatric center, assessed self-reported life engagement—a metric encompassing motivation, social participation, and daily functioning—after a standard ketamine protocol. Approximately 30% of participants did not report meaningful improvements, despite adequate dosing and adherence to clinical guidelines.

This research is significant because it shifts the focus from symptom reduction alone to broader measures of well-being, revealing that non-response is not solely defined by unchanged depression scores but also by lack of improvement in patients' perceived quality of life.

Mechanisms and Clinical Correlates of Non-Response

Non-response to ketamine in TRD appears to be associated with specific clinical features, according to the study's multivariate analysis. Patients with higher baseline levels of anhedonia (inability to feel pleasure), chronicity of depressive episodes, and comorbid anxiety disorders were less likely to report increased life engagement after treatment. The study also found that individuals with a history of poor response to multiple antidepressant classes showed lower rates of subjective improvement.

Importantly, the research suggests that biological or psychosocial factors—such as inflammatory markers or social isolation—may play a role in non-response, though these hypotheses require further investigation. The authors note that self-assessed life engagement may capture dimensions of recovery that traditional depression scales miss, underscoring the need for multidimensional outcome measures in psychedelic trials.

Implications for Clinical Trials and Policy

Understanding clinical correlates of non-response to ketamine has immediate implications for ongoing and future psychedelic-assisted therapy trials. Trial designers may consider stratifying participants by baseline anhedonia or chronicity to better interpret efficacy signals and reduce placebo effects. This approach could also inform adaptive trial designs and help avoid overestimating the generalizability of positive results.

For clinicians, these findings highlight the importance of comprehensive pre-treatment assessments and the potential value of integrating self-assessed life engagement into routine outcome monitoring. Policy makers and regulators, including the U.S. Food and Drug Administration (FDA), may look to such multidimensional endpoints when evaluating new drug applications for TRD and related indications. Notably, the study's focus on self-reported life engagement aligns with recent FDA guidance emphasizing patient-centered outcomes (FDA Patient-Focused Drug Development Guidance).

Risks, Unknowns, and the Need for Further Research

While the study offers valuable insights, several risks and unknowns remain. The reliance on self-assessed life engagement introduces subjectivity, and the lack of biomarker data limits mechanistic understanding. There is also a risk that excluding non-responders from future trials could inadvertently narrow the therapeutic window or miss subgroups who might benefit from adjunctive interventions.

Additionally, the study does not address long-term outcomes or the potential for delayed response, which are critical considerations for both clinical practice and regulatory approval. Real-world implementation may face challenges in standardizing life engagement assessments across diverse populations and care settings.

Looking Ahead: Toward Personalized Psychedelic Therapies

The identification of clinical correlates among ketamine non-responders in TRD marks a step toward more personalized approaches in psychedelic medicine. Future research should prioritize biomarker discovery, longitudinal follow-up, and the integration of patient-reported outcomes into both clinical trials and routine care. Stakeholders—including clinicians, researchers, and policy makers—will need to balance the promise of rapid-acting interventions with the complexities of heterogeneous patient populations and nuanced definitions of treatment success.

One non-obvious implication is that refining inclusion criteria based on life engagement predictors may improve both trial efficiency and real-world effectiveness, but could also introduce new equity concerns if certain subgroups are systematically excluded. Transparent reporting and adaptive trial methodologies will be essential to ensure that advances in psychedelic research translate into meaningful benefits for all patients with TRD.

How we research: This analysis was written and reviewed by Dr. Alex M. Carter, MD, PhD (Board-Certified Psychiatrist, Clinical Trials Principal Investigator). Reviewed on 2026-09-12. Primary sources include the original OpenAlex article and FDA guidance documents.